ACHIEVE LIFE SCIENCES Files 8-K on Financial Results
Ticker: ACHV · Form: 8-K · Filed: Mar 24, 2026 · CIK: 0000949858
| Field | Detail |
|---|---|
| Company | Achieve Life Sciences, Inc. (ACHV) |
| Form Type | 8-K |
| Filed Date | Mar 24, 2026 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: earnings, financial-results, 8-K, corporate-filing
TL;DR
**ACHIEVE LIFE SCIENCES just dropped an 8-K, likely signaling financial results are out; check the exhibits for the numbers!**
AI Summary
ACHIEVE LIFE SCIENCES, INC. filed an 8-K on March 24, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). This filing indicates the company is likely releasing or has just released its financial results, which are crucial for investors to understand the company's performance and future prospects. Investors should pay close attention to the details in the accompanying exhibits, especially EX-99.1, to assess the company's financial health and operational efficiency.
Why It Matters
This filing signals the release of financial results, which directly impacts how investors perceive the company's value and future potential. Understanding these results is key to making informed investment decisions.
Risk Assessment
Risk Level: medium — The risk is medium because while the filing itself is routine, the financial results it contains could significantly impact the stock price, either positively or negatively.
Analyst Insight
A smart investor would immediately locate and review the EX-99.1 exhibit to understand the detailed financial results and any forward-looking statements, then compare these results against analyst expectations and historical performance to assess the company's current valuation.
Key Players & Entities
- ACHIEVE LIFE SCIENCES, INC. (company) — the filer of the 8-K
- 0000949858 (company) — CIK of ACHIEVE LIFE SCIENCES, INC.
- 2026-03-24 (date) — filing date and period of report
FAQ
What specific items did ACHIEVE LIFE SCIENCES, INC. report on in this 8-K filing?
ACHIEVE LIFE SCIENCES, INC. reported on Item 2.02: Results of Operations and Financial Condition, and Item 9.01: Financial Statements and Exhibits, as indicated in the filing dated March 24, 2026.
What is the significance of the EX-99.1 exhibit mentioned in the filing?
The EX-99.1 exhibit (achv-ex99_1.htm) is likely a press release or other document containing the detailed financial results and operational updates, which is critical for investors to review for specific performance metrics.
Filing Stats: 534 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2026-03-24 07:05:07
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share ACHV The Nasdaq Stock Mar
Filing Documents
- achv-20260324.htm (8-K) — 54KB
- achv-ex99_1.htm (EX-99.1) — 289KB
- img9551541_0.jpg (GRAPHIC) — 21KB
- 0001193125-26-120687.txt ( ) — 529KB
- achv-20260324.xsd (EX-101.SCH) — 50KB
- achv-20260324_htm.xml (XML) — 6KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On March 24, 2026, Achieve Life Sciences, Inc. issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 104 Press release of Achieve Life Sciences, Inc. dated March 24, 2026 Cover Page Interactive Data File (embedded within the Inline XBRL document) ________________________ The information in Item 2.02 of this Form 8-K and Exhibit 99.1 attached hereto is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. ________________________
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ACHIEVE LIFE SCIENCES, INC. Date: March 24, 2026 /s/ MARK OKI Mark Oki Chief Financial Officer (Principal Financial Officer)